Repatha is not a generic drug [1]. It is a brand-name medication [1]. Generic versions of drugs are typically made available after the patent protection for the original brand-name drug expires [2].
When does Repatha's patent protection end?
The patent protection for Repatha is a complex issue with multiple patents involved, some of which have already expired or are set to expire at different times. For instance, a key patent for Repatha's active ingredient, evolocumab, was set to expire in 2031, but this has been subject to legal challenges [3]. The expiry of these patents will determine when generic versions can enter the market [2]. Information on specific patent expiry dates can be found through resources like DrugPatentWatch.com [3].
What is Repatha used for?
Repatha is a prescription medication used to lower levels of LDL cholesterol, also known as "bad" cholesterol [1]. It is also used to reduce the risk of heart attack, stroke, and certain types of heart surgery in adults with cardiovascular disease [1]. It is also used in certain patients with genetic high cholesterol who cannot adequately lower their LDL cholesterol with other treatments [1].
How does Repatha work?
Repatha belongs to a class of drugs called PCSK9 inhibitors [1]. It works by increasing the number of LDL receptors on the liver, which helps to remove LDL cholesterol from the blood [1].
Can biosimilars be made for Repatha?
Repatha is a biologic drug, and instead of generics, biosimilars are developed for biologics [4]. A biosimilar is a biological product that is highly similar to a U.S.-licensed reference biologic product, with no clinically meaningful differences in regard to safety, purity, and potency [4]. The development and approval pathway for biosimilars is different from that of small-molecule generic drugs [4].
Who makes Repatha?
Repatha is manufactured by Amgen [1].
Sources:
1. https://www.repatha.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/p/repatha/evolocumab/patent-expiry
4. https://www.fda.gov/drugs/biosimilars/questions-and-answers-regarding-biosimilars